



Clinical trial results:

Open-label, prospective, single-arm pilot study to evaluate the efficacy and safety of a ritonavir dose reduction in HIV-infected patients receiving tipranavir/ritonavir 500/200 mg each 12 hours

Summary

EudraCT number	2007-004825-35
Trial protocol	ES
Global end of trial date	20 May 2009

Results information

Result version number	v1 (current)
This version publication date	09 August 2017
First version publication date	09 August 2017

Trial information

Trial identification

Sponsor protocol code	TPVRTV_500100_IQ
-----------------------	------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00607958
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Fundació Lluita contra la SIDA
Sponsor organisation address	Crta de Canyet s/n, Badalona, Spain, 08916
Public contact	CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14, rescrig@flsida.org
Scientific contact	CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 May 2009
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 May 2009
Global end of trial reached?	Yes
Global end of trial date	20 May 2009
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Evaluate the efficacy and safety of a ritonavir dose reduction to 100 mg bid guided by the tipranavir virtual inhibitory quotient (vIQ) in HIV -infected patients receiving tipranavir/ritonavir 500/200 mg bid whose viral load was <50 copies/mL and whose tipranavir vIQ was >60.

Protection of trial subjects:

not specific

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 December 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 11
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	11
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Twenty-four eligible participants were identified from a compiled database

Pre-assignment

Screening details:

Eleven patients were finally enrolled in the study

Period 1

Period 1 title	overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Experimental arm
-----------	------------------

Arm description:

patients receiving salvage antiretroviral therapy containing tipranavir/ritonavir 500/100 mg bid who reduced their dose to 100 mg bid at enrollment

Arm type	Experimental
Investigational medicinal product name	Tipranavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

capsules 250 mg (2 capsule each 12 h)

Investigational medicinal product name	ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

capsules 100 mg (1 capsule each 12 h)

Number of subjects in period 1	Experimental arm
Started	11
Completed	9
Not completed	2
safety measure	1
Lack of efficacy	1

Baseline characteristics

Reporting groups

Reporting group title	overall
-----------------------	---------

Reporting group description: -

Reporting group values	overall	Total	
Number of subjects	11	11	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	11	11	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
median	43		
inter-quartile range (Q1-Q3)	40 to 45	-	
Gender categorical			
Units: Subjects			
Female	3	3	
Male	8	8	

End points

End points reporting groups

Reporting group title	Experimental arm
Reporting group description: patients receiving salvage antiretroviral therapy containing tipranavir/ritonavir 500/100 mg bid who reduced their dose to 100 mg bid at enrollment	

Primary: percentage of patients without therapeutic failure

End point title	percentage of patients without therapeutic failure ^[1]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

week 48

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Ten of the 11 participants (90.9%) in the study maintained a viral load <50 copies/mL at week 48. Nothing to compare

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: percentage (%)				
number (not applicable)	90.9			

Statistical analyses

No statistical analyses for this end point

Secondary: Increase CD4+ T-cell count

End point title	Increase CD4+ T-cell count
-----------------	----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

week 48

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: cells/mm3				
median (inter-quartile range (Q1-Q3))	76 (23 to 214)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in lipid profile: total cholesterol

End point title	changes in lipid profile: total cholesterol
End point description:	
End point type	Secondary
End point timeframe:	
from baseline to week 48	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dL				
median (inter-quartile range (Q1-Q3))				
baseline	209 (178 to 263.2)			
week 48	194 (174 to 232)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in lipid profile: HDL-cholesterol

End point title	changes in lipid profile: HDL-cholesterol
End point description:	
End point type	Secondary
End point timeframe:	
from baseline to week 48	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dL				
median (inter-quartile range (Q1-Q3))				
baseline	50.7 (46.4 to 73.1)			
week 48	54.2 (45.7 to 65)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in lipid profile: LDL-cholesterol

End point title	changes in lipid profile: LDL-cholesterol
End point description:	
End point type	Secondary
End point timeframe:	
from baseline to week 48	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dL				
median (inter-quartile range (Q1-Q3))				
baseline	100.6 (64.2 to 138.5)			
week 48	107.8 (95.5 to 146.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in lipid profile: Triglycerides

End point title	changes in lipid profile: Triglycerides
End point description:	
End point type	Secondary
End point timeframe:	
from baseline to week 48	

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dL				
median (inter-quartile range (Q1-Q3))				
baseline	177.2 (132.9 to 292.4)			
week 48	158 (131 to 186)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in liver enzymes: AST

End point title	changes in liver enzymes: AST
-----------------	-------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

from baseline to week 48

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: IU/L				
median (inter-quartile range (Q1-Q3))				
baseline	39 (24 to 84)			
week 48	26 (22 to 31)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes in liver enzymes: ALT

End point title	changes in liver enzymes: ALT
-----------------	-------------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:
from baseline to week 48

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: IU/L				
median (inter-quartile range (Q1-Q3))				
baseline	59 (23 to 128)			
week 48	28 (20 to 71)			

Statistical analyses

No statistical analyses for this end point

Secondary: ritonavir Ctrough

End point title ritonavir Ctrough

End point description:

End point type Secondary

End point timeframe:
from baseline to week 48

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/L				
geometric mean (confidence interval 95%)				
baseline	0.38 (0.2 to 0.71)			
week 48	0.12 (0.06 to 0.22)			

Statistical analyses

No statistical analyses for this end point

Secondary: tipranavir Ctrough

End point title tipranavir Ctrough

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:
from baseline to week 48

End point values	Experimental arm			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/L				
geometric mean (confidence interval 95%)				
baseline	24.7 (12.9 to 47.5)			
week 48	13.6 (7.1 to 26.2)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

from baseline to week 48

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	DAIDS AE GRADING TAB
-----------------	----------------------

Dictionary version	1.0
--------------------	-----

Reporting groups

Reporting group title	experimental arm
-----------------------	------------------

Reporting group description: -

Serious adverse events	experimental arm		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 11 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	experimental arm		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 11 (9.09%)		
Gastrointestinal disorders			
Gastrointestinal disorder	Additional description: gastrointestinal intolerance and lip id and liver enzyme elevations		
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 April 2008	treatment follow up changed from 24 to 48 week

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported